FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3000685986> ?p ?o ?g. }

• W3000685986 endingPage "S431" @default.
• W3000685986 startingPage "S431" @default.
• W3000685986 abstract "Abstract Background Objective goals are needed to guide patient management and assess treatment efficacy in patients with Crohn’s disease (CD). Bowel ultrasound (US) is a widely available, non-invasive and inexpensive technique increasingly being used in these patients. The use of bowel wall thickness (BWT) has been proved to be an accurate measure for assessing disease activity and response to therapy. Recent studies show a rapid improvement of BWT after 3-month of therapy. Our aim was to evaluate BWT variation after induction therapy with infliximab (IFX) in CD patients and correlate BWT with clinical and laboratory parameters. Methods Prospective cohort multicentre study including patients with active CD starting IFX therapy. Clinical disease activity was assessed using the Harvey–Bradshaw index (HBI). C-reactive protein (CRP) and faecal calprotectin (FC) were measured both at week 0 and after induction therapy (week 14), and infliximab trough levels (ITL) were measured at week 14. Bowel ultrasound was performed at week 0 and 14, BWT from the worst segment was selected for analysis. Abnormal BWT was defined has higher than 3mm in any bowel segment. Results We included 10 patients with CD (80% males; median age 29 (21–64) years). According to Montreal classification, most patients were A2 (7/10), had ileocolonic disease (L1 20%; L2 20%; L3 60%) and an inflammatory phenotype (B1 60%; B2 20% and B3 20%). Most patients were anti-TNF therapy naive (80%), and combination therapy was used in 80%. Before IFX (week 0) median HBI was 2 (IQR 1.75–5.25), CRP 1.10 mg/dl (IQR 0.65–3.50) and FC 802 μg/g (IQR 324–1336). The terminal ileum was the most affected segment identified by the USA (5/10), followed by ascending colon (2/10) descending colon (2/10) and sigmoid colon (1/10). Median BWT was 4.6 mm (IQR 3.6–6.4). After induction therapy (week 14), all patients were in clinical remission (HBI&lt;5) except for one in whom IFX dose was increased to 10 mg/kg. Laboratory remission (CRP &lt; 0.5 mg/dl and FC &lt; 250 μg/g) was present in 50% of patients. US response (measured by a reduction in BWT of at least 0.5 mm) was observed in 70% of patients, with US remission (normalisation of BWT in the most affected segment) in 30%. At week 14, 70% of patient had ITL &gt; 3 μg/ml. Median BWT at week 14 was higher in patients with ITL &lt; 3 μg/ml (6.25 vs. 2.98 mm, p = 0.048). Conclusion The majority of our patients showed a US response (reduction in BWT) after 14 weeks of infliximab, suggesting that reduction in BWT could be an early marker of response to therapy. US evaluation after induction therapy can be a helpful tool to monitor disease activity and guide patient management in CD patients in our daily practice." @default.
• W3000685986 created "2020-01-23" @default.
• W3000685986 creator A5005445685 @default.
• W3000685986 creator A5011103862 @default.
• W3000685986 creator A5022032308 @default.
• W3000685986 creator A5022486474 @default.
• W3000685986 creator A5023779315 @default.
• W3000685986 creator A5043739294 @default.
• W3000685986 creator A5050991456 @default.
• W3000685986 creator A5053000933 @default.
• W3000685986 creator A5056761118 @default.
• W3000685986 creator A5065822684 @default.
• W3000685986 creator A5066561361 @default.
• W3000685986 creator A5067361644 @default.
• W3000685986 creator A5073936180 @default.
• W3000685986 creator A5079423888 @default.
• W3000685986 creator A5084052362 @default.
• W3000685986 date "2020-01-01" @default.
• W3000685986 modified "2023-10-18" @default.
• W3000685986 title "P492 Use of bowel ultrasound to assess disease activity in Crohn’s disease patients after induction therapy with infliximab" @default.
• W3000685986 doi "https://doi.org/10.1093/ecco-jcc/jjz203.621" @default.
• W3000685986 hasPublicationYear "2020" @default.
• W3000685986 type Work @default.
• W3000685986 sameAs 3000685986 @default.
• W3000685986 citedByCount "2" @default.
• W3000685986 countsByYear W30006859862021 @default.
• W3000685986 countsByYear W30006859862023 @default.
• W3000685986 crossrefType "journal-article" @default.
• W3000685986 hasAuthorship W3000685986A5005445685 @default.
• W3000685986 hasAuthorship W3000685986A5011103862 @default.
• W3000685986 hasAuthorship W3000685986A5022032308 @default.
• W3000685986 hasAuthorship W3000685986A5022486474 @default.
• W3000685986 hasAuthorship W3000685986A5023779315 @default.
• W3000685986 hasAuthorship W3000685986A5043739294 @default.
• W3000685986 hasAuthorship W3000685986A5050991456 @default.
• W3000685986 hasAuthorship W3000685986A5053000933 @default.
• W3000685986 hasAuthorship W3000685986A5056761118 @default.
• W3000685986 hasAuthorship W3000685986A5065822684 @default.
• W3000685986 hasAuthorship W3000685986A5066561361 @default.
• W3000685986 hasAuthorship W3000685986A5067361644 @default.
• W3000685986 hasAuthorship W3000685986A5073936180 @default.
• W3000685986 hasAuthorship W3000685986A5079423888 @default.
• W3000685986 hasAuthorship W3000685986A5084052362 @default.
• W3000685986 hasBestOaLocation W30006859861 @default.
• W3000685986 hasConcept C126322002 @default.
• W3000685986 hasConcept C188816634 @default.
• W3000685986 hasConcept C2777138892 @default.
• W3000685986 hasConcept C2778260677 @default.
• W3000685986 hasConcept C2778292693 @default.
• W3000685986 hasConcept C2779008522 @default.
• W3000685986 hasConcept C2779134260 @default.
• W3000685986 hasConcept C2779280984 @default.
• W3000685986 hasConcept C71924100 @default.
• W3000685986 hasConcept C72563966 @default.
• W3000685986 hasConcept C90924648 @default.
• W3000685986 hasConceptScore W3000685986C126322002 @default.
• W3000685986 hasConceptScore W3000685986C188816634 @default.
• W3000685986 hasConceptScore W3000685986C2777138892 @default.
• W3000685986 hasConceptScore W3000685986C2778260677 @default.
• W3000685986 hasConceptScore W3000685986C2778292693 @default.
• W3000685986 hasConceptScore W3000685986C2779008522 @default.
• W3000685986 hasConceptScore W3000685986C2779134260 @default.
• W3000685986 hasConceptScore W3000685986C2779280984 @default.
• W3000685986 hasConceptScore W3000685986C71924100 @default.
• W3000685986 hasConceptScore W3000685986C72563966 @default.
• W3000685986 hasConceptScore W3000685986C90924648 @default.
• W3000685986 hasIssue "Supplement_1" @default.
• W3000685986 hasLocation W30006859861 @default.
• W3000685986 hasOpenAccess W3000685986 @default.
• W3000685986 hasPrimaryLocation W30006859861 @default.
• W3000685986 hasRelatedWork W1997465236 @default.
• W3000685986 hasRelatedWork W2105067435 @default.
• W3000685986 hasRelatedWork W2105895988 @default.
• W3000685986 hasRelatedWork W2150235762 @default.
• W3000685986 hasRelatedWork W2161661686 @default.
• W3000685986 hasRelatedWork W2951213298 @default.
• W3000685986 hasRelatedWork W3171159932 @default.
• W3000685986 hasRelatedWork W3172693904 @default.
• W3000685986 hasRelatedWork W4221080391 @default.
• W3000685986 hasRelatedWork W3145889094 @default.
• W3000685986 hasVolume "14" @default.
• W3000685986 isParatext "false" @default.
• W3000685986 isRetracted "false" @default.
• W3000685986 magId "3000685986" @default.
• W3000685986 workType "article" @default.